The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Long-term effects of tetrabenazine in hyperkinetic movement disorders
Abstract
Over the past 15 years we have treated 526 patients with severe hyperkinetic movement disorders with tetrabenazine (TBZ), a monoamine-depleting and a dopamine-receptor-blocking drug. We report here the results in 400 patients with adequate follow-up. The response was rated on a scale of 1 to 5 (1 = marked improvement, 4 = no response, 5 = worsening) and was assessed initially and at the last clinic visit. The average duration of TBZ treatment was 28.9 months (+/- 31.1; range, 0.25 to 180 months). The global response rating of 1 (marked improvement) was recorded in 89.2% of 93 patients with tardive stereotypy, 83.3% of 12 with myoclonus, 82.8% of 29 with Huntington's disease, 80.5% of 82 with tardive dystonia, 79.3% of 29 with other movement disorders, 62.9% of 108 with idiopathic dystonia, and in 57.4% of 47 with Tourette's syndrome. The most common side effects included drowsiness (36.5%), parkinsonism (28.5%), depression (15.0%), insomnia (11.0%), nervousness or anxiety (10.3%), and akathisia (9.5%). The side effects were controlled with reduction in the dosage. TBZ is an effective and safe drug for the treatment of a variety of hyperkinetic movement disorders. In contrast to typical neuroleptics, TBZ has not been demonstrated to cause tardive dyskinesia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacologic distinction of different orthostatic hypotension syndromes
Polinsky, R. J., Kopin, I. J., Ebert, M. H., & Weise, V. (1981) · Neurology · doi:10.1212/wnl.31.1.1 · Cited by 296
Creasey, H., & Rapoport, S. I. (1985) · Annals of Neurology · doi:10.1002/ana.410170103 · Cited by 246
Evaluation of thermography in the diagnosis of selected entrapment neuropathies
So, Y. T., Olney, R. K., & Aminoff, M. J. (1989) · Neurology · doi:10.1212/wnl.39.1.1 · Cited by 171
Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome
Jankovic, J. J., Glaze, D. G., & Frost, J. D. (1984) · Neurology · doi:10.1212/wnl.34.5.688 · Cited by 129
Self-citationNeuronal inclusions of Parkinson's disease
Gibb, W. R. G., Scott, T., & Lees, A. J. (1991) · Movement Disorders · doi:10.1002/mds.870060103 · Cited by 113
Recent Advances in Treatment of Acute Mania
CHOU, J. C. Y. (1991) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199102000-00002 · Cited by 86
Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain.
Reches, A., Burke, R. E., Kuhn, C. M., Hassan, M. N., Jackson, V., & Fahn, S. (1983) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)33621-9 · Cited by 75
A DOUBLE-BLIND TRIAL OF TETRABENAZINE, THIOPROPAZATE, AND PLACEBO IN PATIENTS WITH CHOREA
McLellan, D. L. (1974) · The Lancet · doi:10.1016/s0140-6736(74)92338-1 · Cited by 72
Tetrabenazine has properties of a dopamine receptor antagonist
Login, I. S., Cronin, M. J., & MacLeod, R. M. (1982) · Annals of Neurology · doi:10.1002/ana.410120308 · Cited by 67
Gilman, S. (1982) · Neurology · doi:10.1212/wnl.32.1.1 · Cited by 49
Cited by
Tourette syndrome, associated conditions and the complexities of treatment
Robertson, M. M. (2000) · Brain · doi:10.1093/brain/123.3.425 · Cited by 704
Leckman, J. F. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11526-1 · Cited by 685
Stuttering and the basal ganglia circuits: a critical review of possible relations
Alm, P. A. (2004) · Journal of Communication Disorders · doi:10.1016/j.jcomdis.2004.03.001 · Cited by 556
Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial
Huntington Study Group (2006) · Neurology · doi:10.1212/01.wnl.0000198586.85250.13 · Cited by 471
the ESSTS Guidelines Group, Roessner, V., Plessen, K. J., Rothenberger, A., Ludolph, A. G., Rizzo, R., Skov, L., Strand, G., Stern, J. S., Termine, C., et al. (2011) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-011-0163-7 · Cited by 461
Jankovic, J. (2001) · New England Journal of Medicine · doi:10.1056/nejmra010032 · Cited by 447
Self-citationHauser, R. A., Factor, S. A., Marder, S. R., Knesevich, M. A., Ramirez, P. M., Jimenez, R., Burke, J., Liang, G. S., & O’Brien, C. F. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16091037 · Cited by 392
Jankovic, J. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70574-9 · Cited by 332
Self-citationContemporary assessment and pharmacotherapy of Tourette syndrome
Scahill, L., Erenberg, G., Berlin, C. M., Budman, C., Coffey, B. J., Jankovic, J., Kiessling, L., King, R. A., Kurlan, R., Lang, A., et al. (2006) · NeuroRX · doi:10.1016/j.nurx.2006.01.009 · Cited by 300
Self-citationTetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial
Savani, A. A., & Login, I. S. (2007) · Neurology · doi:10.1212/01.wnl.0000259143.52138.5c · Cited by 299
Comparative effects of unilateral and bilateral subthalamic nucleus deep brain stimulation
Kumar, R., Lozano, A. M., Sime, E., Halket, E., & Lang, A. E. (1999) · Neurology · doi:10.1212/wnl.53.3.561 · Cited by 290
Albanese, A., Barnes, M. P., Bhatia, K. P., Fernandez‐Alvarez, E., Filippini, G., Gasser, T., Krauss, J. K., Newton, A., Rektor, I., Savoiardo, M., et al. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01537.x · Cited by 280
Dissecting the role of the serotonin system in neuropsychiatric disorders using knockout mice
Gingrich, J. A., & Hen, R. (2001) · Psychopharmacology · doi:10.1007/s002130000573 · Cited by 265
Treatment strategies for tics in Tourette syndrome
Eddy, C. M., Rickards, H. E., & Cavanna, A. E. (2011) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285610390261 · Cited by 158
Vesicular monoamine transporter 2: Role as a novel target for drug development
Zheng, G., Dwoskin, L. P., & Crooks, P. A. (2006) · The AAPS Journal · doi:10.1208/aapsj080478 · Cited by 125
STEEVES, T., & FOX, S. (2008) · Progress in Brain Research · doi:10.1016/s0079-6123(08)00924-2 · Cited by 79
The role of the autonomic nervous system in Tourette Syndrome
Hawksley, J., Cavanna, A. E., & Nagai, Y. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00117 · Cited by 56
Fasano, A., & Bentivoglio, A. R. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903386292 · Cited by 51
Metadata
- Authors
- Jankovic, J., & Beach, J.
- Venue
- Neurology
- Published
- 1997-02
- Volume
- 48
- Issue
- 2
- Pages
- 358-362
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2117670094
- Cited by
- 352
- References
- 12
- FWCI
- 8.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.